DEFINITY RT (perflutren) by Lantheus Medical Imaging is ultrasound contrast activity [moa]. First approved in 2001.
Drug data last refreshed 1h ago · AI intelligence enriched Yesterday
DEFINITY RT (perflutren) is an intravenous ultrasound contrast agent approved in 2001 that enhances visualization of cardiac structures and blood flow during echocardiography. It works by creating microbubbles that reflect ultrasound waves, improving image quality for diagnostic assessment. The product is indicated for left ventricular opacification in patients with suboptimal echocardiograms.
Mature product in peak lifecycle stage; team size likely stable with focus on market maintenance and operational efficiency rather than growth initiatives.
Ultrasound Contrast Activity
Contrast Agent for Ultrasound Imaging
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on DEFINITY RT offers stable career opportunities in a mature, profitable diagnostic imaging franchise with established market position and minimal disruption risk. Roles emphasize operational excellence, physician engagement, and market maintenance rather than launch execution or rapid growth management.
Worked on DEFINITY RT at Lantheus Medical Imaging? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo